Granted Patent
B2
US 10,973,924 · App. 16/142,354 · Granted Apr 13, 2021
Antibody-drug conjugate
Inventors:
Takeshi Masuda (Tokyo, JP); Hiroyuki Naito (Tokyo, JP); Takashi Nakada (Tokyo, JP); Masao Yoshida (Tokyo, JP); Shinji Ashida (Tokyo, JP); Hideki Miyazaki (Tokyo, JP); Yuji Kasuya (Tokyo, JP); Koji Morita (Tokyo, JP); Yuki Abe (Tokyo, JP); Yusuke Ogitani (Tokyo, JP)
Assignee:
DAIICHI SANKYO COMPANY, LIMITED
A61K47/6803A61K31/4745A61K31/48C07K16/2803C07K16/2827C07K16/2851C07K16/2875C07K16/2878C07K16/30C07K2317/30C07K2317/77
View Patent ↗
Loading inventors, assignments & file history…
Abstract
As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L 1 -L 2 -L P -NH—(CH 2 )n 1 -L a -L b -L c - wherein the antibody is connected to the terminal of L 1 , and the antitumor compound is connected to the terminal of L c with the nitrogen atom of the amino group at position 1 as a connecting position.
Claims (2)
1. A compound of the following formula:
2. A method for treating a tumor and/or cancer comprising contacting the tumor and/or cancer with a compound of the following formula:
Priority Claims (1)
JP 2012-225887
· Oct 11, 2012
· national
Continuity (2)
Continuation
14435114